NovaBay off big after trial fails

Shares of NovaBay Pharmaceuticals (NYSEMKT:NBY) are off 40% premarket on light volume after the company announced that its ophthalmic formulation for viral conjunctivitis, NVC-422, failed to achieve its primary or secondary endpoints in a Phase 2 clinical trial.

The global study enrolled patients with adenoviral conjunctivitis in the U.S., India, Sri Lanka and Brazil. The endpoints were: measured clearing of bulbar conjunctival injection (red eye); eradication of adenovirus from tear film; spread of infection to the fellow eye; reduction in sub-epithelial infiltrates; clearing of blurred vision compared to its Vehicle at Test-of-Cure Visit (Day 18).

The company has terminated its pursuit of NVC-422 for this indication.

Comments (1)
  • DWD Investing
    , contributor
    Comments (13373) | Send Message
    Could be a death blow.
    20 Aug 2014, 10:06 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs